The leucine-rich, glioma-inactivated (LGI1) gene, located in 10q24, was originally identified because it was interrupted and inactivated by a reciprocal chromosome translocation in the T98G glioma cell line. Loss of LGI1 expression in high-grade brain tumors is correlated with the frequent loss of chromosome 10 during progression of gliomas. To investigate whether this gene can suppress the malignant phenotype in glioma cells, we introduced the LGI1 gene into cells that do (U87) and do not (T98G and A172) express LGI1 endogenously. A172 and T98G cells showed a significant reduction in cell proliferation potential as a result of re-expression of LGI1, whereas U87 cells did not. Using BD matrigel matrix chamber assays we were also able to show that the migration ability of the reconstituted A172 and T98G cells was also reduced considerably. Finally, these reconstituted T98G and A172 cells showed a significant reduction in the ability to form colonies in soft agar compared with the parental cells. This analysis clearly demonstrates that re-expression of the LGI1 gene in glioma cells that were null for its activity can greatly reduce their malignant potential. These observations provide the opportunity to investigate the role of LGI1 in gliomagenesis and, since LGI1 is predicted to be a membrane-bound protein, potentially provides the opportunity to develop novel treatment strategies for malignant gliomas.
Introduction
Gliomas take a number of different genetic routes to the highly invasive glioblastoma multiforme (GBM). Thus, some inactivate the p53 gene but others do not. Some amplify the EGFR gene and others do not (Kleihues and Cavenee, 2000) . Molecular genetic analysis of tumors with different etiologies and histopathologies demonstrates one unique feature, however, with virtually all GBM showing loss of material from chromosome 10 regardless of the other genetic changes that they have acquired. Up to 90% of GBM tumors show loss of chromosome 10 material. In the majority of cases (70-80%) this loss manifests as loss of the whole chromosome (James et al., 1988; Fults et al., 1990; Rasheed et al., 1992; Albarosa et al., 1996) , but in a small percentage of tumors it has been possible, using classical loss of heterozygosity studies, to demonstrate that subregional loss has occurred (Fults et al., 1992; Ransom et al., 1992; Rasheed et al., 1992; Fults and Pedone, 1993; Karlbom et al., 1993) . From these studies, three areas of the chromosome appear to represent the critical regions: 10p11, 10q24 and 10q26 (Steck et al., 1995) . In some cases, these losses appear to be mutually exclusive suggesting that there may well be a number of different genes on chromosome 10 that are important for gliomagenesis, which might also account for the observation that the most frequent event is the loss of the whole chromosome. Transfer of an intact copy of chromosome 10 from normal cells into GBM cell lines results in suppression of malignancy, which further supports the suggestion that critical glioma genes are located on this chromosome (Pershouse et al., 1993) . The fact that the whole chromosome is lost, however, makes it difficult to incriminate any particular gene.
There have been a number of candidate glioma genes from chromosome 10 that have been characterized to date. The PTEN gene (Li and Sun, 1997; Myers et al., 1997; Steck et al., 1997) , which lies in 10q23, and outside of the regions of 10q implicated in LOH studies, has been shown to be mutated in gliomas and these studies suggest that anywhere from 25 to 60% of tumors carry mutations in this gene, although the consensus appears to be nearer 25% Rasheed et al., 1997; Wang et al., 1997) . The DMBT gene (Mollenhauer et al., 1997) , which lies in 10q26, has also been implicated in gliomagenesis in a number of reports (Mollenhauer et al., 1997 , although more recent results suggest that DMBT is not as involved in gliomagenesis as was first thought (Sasaki et al., 2002) . What is clear, however, is that mutations in these genes are not involved in the majority of gliomas, which suggests that there are other genes on this chromosome that are involved in the neoplastic process.
In order to identify candidate genes on chromosome 10 in brain tumors, we explored the possibility that reciprocal chromosome translocations, when they occur on a background of loss of one copy of chromosome 10, serve as a means to inactivate genes involved in gliomagenesis. Chromosome translocations have repeatedly proved to be part of the spectrum of mutational events that affect the function of genes in tumor cells. The reciprocal nature of these chromosome translocations implies that there is no gain or loss of chromosome material and so it is likely that the gene interrupted by the chromosome translocation is involved in the development of tumorigenesis. Using this strategy, we identified the A172 cell line, which carries a reciprocal t(10;19)(q26;q13.4) rearrangement that interrupts the WDR11 gene on chromosome 10 (Chernova et al., 2001) and potentially identifies a gene associated with LOH from this region. Our analysis of the T98G cell line identified a reciprocal t(10;19)(q24;q13.1) that interrupted the LGI1 gene on chromosome 10q24. The LGI1 gene is inactivated in most high-grade gliomas but present in some low-grade tumors (Chernova et al., 1998) .
LGI1 is also rearranged and inactivated in the A172 cell line. Several other cell lines show expression of LGI1, including the U87 cell line, reportedly derived from an astrocytoma. Our preliminary studies have failed to identify specific mutations within the coding region of LGI1 (Somerville et al., 2000) , although structural chromosome rearrangements were indicated in up to 25% of high-grade tumors (Chernova et al., 1998) . The observation that some tumors express LGI1 and others do not suggests, as with PTEN, that it may be an important glioma gene in a subset of tumors, but that others have developed alternative genetic routes to malignancy that do not involve LGI1.
The involvement of specific genes in the tumorigenesis can be confirmed by reconstituting cells with the gene that are null for its activity. The reintroduction of the gene is expected to alter the biological properties of the cell which, in vitro, usually involves cell proliferation potential, the ability to migrate through a matrigel matrix, as well as to grow under anchorage-independent conditions in soft agar. In this report, we demonstrate suppression of the malignant phenotype in the A172 and T98G cell lines which do not express LGI1, but not in the U87 cell line which does express LGI1. The experiments clearly demonstrate that the malignant phenotype of glioma cells can be affected by the re-expression of LGI1 in cell lines null for its activity and provide strong support for its role in suppression of gliomagenesis.
Materials and methods

Cell culture and transfection studies
The GBM-derived T98G (Stein, 1979) and A172 (Giard et al., 1973) cell lines, and the grade III astocytoma-derived U87 cell line (Ponten and Macintyre, 1968) were maintained in DMEM with 10% FBS under 10% CO 2 . Cells were transferred using trypsin/EDTA. For transfection, the DNA : liposome (Lipofectamine, Gibco) complex with 100 ng DNA : 10 ml Lipofectamine was allowed to form for 30 min in a 200 ml volume. The cells, at 70-80% confluence in 60 mm dishes, were washed with PBS followed by serum-free DMEM medium and the liposome : DNA complex was added to the cells in 1 ml of serum-free DMEM for 30 s, whereafter 1 ml of DMEM was added and the cells were left for a further 6 h. Finally, 2 ml of DMEM þ 20% FBS were added. After 24 h, the transfected cells were challenged with G418 (Geneticin sulfate) and left for 2-3 weeks with change of medium every 3 days, after which resistant colonies were isolated by ring cloning.
RT-PCR analysis
RNA was isolated from harvested cells using the Rneasy minikit (Qiagen). cDNA was made using SuperscriptII (Invitrogen) and oligo-dT primers. cDNA (1 mg) was used for each PCR reaction using the forward primer, LGI1F (TGTTTGGT-GGCTCTCACATC), and the reverse primer, LGI1R (TGCG-TACACATCCTCCATGT). The primers were from sequence 1129-1526, which generates a 398 bp PCR product.
Western blot analysis
Expression of the LGI1 protein in cell lines stably transfected with pcDNA3LGI1FLAG was analysed using Western blotting. Cells were harvested at 80% confluence, washed twice with PBS and then lysed in RIPA buffer (50 mm Tris containing 150 mm NaCl, 1% sodium deoxycholate, 0.1% SDS and 1% Triton X-100) containing 0.2% Protease inhibitor cocktail (Calbiochem). The extract was kept on ice for 10 min and, after centrifugation at 14 000 Â g for 20 min, the supernatant was recovered. Protein concentrations were determined using the Bio-Rad protein assay method. Cell extracts containing 40 mg of protein were size-fractionated in 4-20% SDS-PAGE gels (BIO-RAD) and electroblotted onto nitrocellulose membranes (BIO-RAD). The membranes were blocked using 5% nonfat dry milk in PBS-Tween-20 (PBS-T) (0.05%) overnight at 41C. A primary antibody used is rabbit polyclonal serum raised against the LGI1 peptides (1 : 1000) or the M2 Flag (1 : 4000) mouse monoclonal antibody (Sigma) diluted in 3% milk in PBS-T and incubated for 3 h at room temperature. The blots were then washed three times with PBS-T for 10 min each and then anti-rabbit-HRP, anti-mouse-HRP antibodies (Jackson Laboratories) were added at 1 : 5000 dilution as secondary antibodies to the respective membranes. After incubation for 1 h at room temperature, the membranes were washed three times with PBS-T for 10 min each. NEN chemiluminescence substrate was added and the blots were developed using Kodak X-Omat AR films. The Actin antibody (Santa Cruz) was used as a loading control.
Quantitation of cell growth
) were seeded in triplicate in tissue culture dishes, and at 24 h intervals the cells were harvested using trypsin. After two washes in PBS, they were resuspended in 1 ml of PBS, and 40 ml of this sample was diluted in counting buffer for quantitation using a coulter counter. Cell numbers were then calculated per milliliter of the original harvest.
Changes in the growth of all the cell lines were also measured using the sulforhodamine B (SRB) colorimetric assay that measures total cellular protein (Papazisis et al., 1997) . Briefly, cells were grown in 96-well plates at various concentrations for 96 h. Growth medium was aspirated, and the cells were fixed by gently adding 50 ml of 10% cold TCA.
Microplates were left at 41C for 30 min, washed five times with deionized water and left to dry at room temperature for 24 h. A 70 ml volume of 0.4% SRB in 1% acetic acid solution was added to each well and the plate was left at room temperature for 20 min. SRB was removed and the plates were washed five times with 1% acetic acid before air drying. SRB bound to the cells was solubilized with 200 ml of 10 mm unbuffered Tris-base
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BD biocoat matrigel invasion assay
These chambers provide conditions that allow the assessment of cellular invasion in vitro. Chambers consist of cell inserts containing an 8 mm pore size PET membrane with a thin layer of matrigel basement membrane matrix. The matrigel, which serves as a reconstituted basement membrane, blocks noninvasive cells from migrating through the membrane. In contrast, invasive cells are able to detach themselves from the membrane and invade through the matrigel matrix and the 8 mm membrane pores. BD matrigel chambers, stored at À201C, were kept at room temperature for 1 h, after which 750 ml of DMEM was added to the wells. The inserts were then transferred to the medium-containing wells. DMEM (500 ml) was added to the inserts and kept at 371C in an incubator with 5% CO 2 for equilibration. After 2 h, the medium in the inserts was aspirated and inserts were placed into the wells containing DMEM and 5% FBS. FBS in this case acts as a chemoattractant for the cells to migrate. In all, 50 000 cells in 500 ml of DMEM were added to the inserts. The plates were incubated for 22 h in a CO 2 incubator at 371C. The chamber inserts were then stained using the Diff-Quick staining kit (Dade-Behring) according to the manufacturer's instructions. Finally, the membranes were separated with a sterile scalpel and observed using a light microscope. The number of cells that had passed through the membranes were counted as a measure of their migration potential.
Soft agar assays
To evaluate the ability of individual cell lines to grow in an anchorage-independent manner, cells were plated in soft agar (Agarose1000; GIBCO BRL) as previously described (Still et al., 1999) . In brief, a 2.5% agarose stock was made in 1 Â PBS. The bottom, 0.5% agar support was prepared in DMEM containing 10% FBS. Cells were harvested, washed and mixed with the top-agarose suspension at a final concentration of 0.3-0.33%, which was then layered onto the bottom agar. The agar plates were incubated at 371C for 10 days, during which time the medium was changed every 3 days. Each assay was performed in triplicate. The number colonies were then counted.
Results
Construction of the LGI1-FLAG gene
The full-length LGI1 open reading frame described by Chernova et al. (1998) was amplified using PCR from fetal brain cDNA at which time the M2-FLAG epitope was incorporated at the C-terminal end using a sequence-specific oligonucleotide. This amplification product was cloned in pBluescript and then transferred into the Kpn1/Not1 site of the pCDNA3 expression vector. Since LGI1 carries a signal peptide at the 5 0 end, which is presumably cleaved off during processing of the gene product, it was not considered prudent to introduce the FLAG-tag at the 5 0 end. The entire construct was then sequence-verified to ensure the accuracy of the gene sequence before transfection.
Transfection studies
RT-PCR analysis of the parental cell lines demonstrated that the T98G and A172 cell lines do not express the LGI1 mRNA (Chernova et al., 1998, Figure 1 ). In contrast, the U87 cell line expresses LGI1 at apparently endogenous levels (Figure 1 ). All three of these cell lines were transfected with the LGI1-FLAG construct described above, and resistant clones were selected using G418. Previous titration assays had established that the A172 and T98G cells required drug concentrations of 500 mg/ml for selection, whereas U87 required only 100 mg/ml. In these experiments, relatively few (10-15) resistant colonies arose initially from the T98G and A172 cells and most of these failed to progress to transferable cultures and eventually died out. These observations suggested that LGI1 has a profound effect on growth potential in these cell lines. Despite this, six independent cell clones could be isolated for each of these cell lines. In contrast, colonies that arose in the LGI1-transfected U87 cells mostly generated progressively growing cultures, suggesting that the same growth inhibitor effect was not operating in this cell line. The presence of the mRNA transcript in these clones was confirmed using RT-PCR (Figure 1 ), which clearly identifies the 398 bp fragment predicted from sequence analysis and the presence of the LGI1 protein was identified using an anti-FLAG antibody (Figure 2 ). The expression levels in the individual clones vary somewhat but, in all of the clones from the T98G-, A172-and U87-transfected cells, the FLAG epitope could be detected. In one T98G clone, T98GFLAG6, the levels of expression were very much lower than those seen in the other clones (Figure 2 ) and the analysis of these cells showed a less significant reduction in cell growth properties (Figure 3 ), possibly implying that the level of suppression is related to the level of LGI1 expression. LGI1 398bp
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LGI1 398bp Figure 1 RT-PCR analysis of clones stably transfected with the LGI1FLAG construct. Cell lines T98G (upper panel) and A172 (middle panel) do not express LGI1 but a PCR product can clearly be seen in six independently isolated G418-resistant clones from each cell line that were transfected with the LGI1FLAG gene. U87 (lower panel) shows endogenous expression of LGI1 (hence also in the vector-transfected control cells) and a higher level of expression in six different G418-resistant clones. All clones show relatively even expression of actin
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Preparation of an LGI1 antibody
Computer prediction programs were used to identify potential antigenic sites within the LGI1 protein. From this analysis two regions were identified, and peptides (1) acetyl-GPPEYKKRKINSLS-MAP and (2) acetyl-LKIRKPNDIETFKI-MAP were prepared as MAP constructs on a polylysine backbone. These peptides were used to immunize two rabbits. Analysis of the serum from each of these two hosts demonstrated that both identified the peptides used for the immunization, but one of these was nonspecific when whole-cell lysates were used. The second antibody, however, identified an apparently specific 60 kDa protein using Western blots carrying extracts from clones from T98G and A172 which had been transfected with the pcDNA3LGI1-FLAG construct. This analysis provided an independent confirmation of the presence of the LGI1 protein in the reconstituted clones. U87-transfected clones showed elevated levels of LGI1 consistent with the presence of the LGI1 protein in G418-resistant clones (Figure 2 ).
Cell growth assays
Initial observations of the T98G and A172 clones suggested that those expressing LGI1 grew more slowly than the parental cells carrying the vector alone, requiring less frequent transfer than the control cells. To quantitate this difference, we undertook cell proliferation assays that counted cells every 24 h from clones which expressed LGI1 (LGI1 þ ) compared with the cell proliferation rate in clones carrying the empty vector (LGI1À) as well as the parental cell line. U87 clones did not show any appreciable difference in their growth rate when compared with the empty vector transfected cells (Figure 3) , whereas T98G and A172 did. In a second approach, total cellular protein was assayed as a measure of growth of these cell lines using the SRB assay. The data presented in Figure 4 show that
LGI1
LGI1 Actin T98G F T98G A172F A172 T98GF6 U87F U87 V 2 3 4 5 6 1 P V 2 3 4 5 6 1 P V 2 3 4 5 6 1 Figure 4 Comparison of growth rates between the parental (P) glioma cell lines and those transfected with either the empty vector (V) or six individually isolated clones expressing the LGI1FLAG (1-6) gene. T98G cells and A172 cells, which do not express LGI1 endogenously, show a marked reduction in growth potential after reintroduction of the LGI1 gene. A less pronounced reduction in growth rate can be seen in clone 6 from the T98G tranfections, which also showed only minimal expression of the reintroduced LGI1 gene. This suggests that the level of expression may be related to the level of growth rate. In contrast, U87 cells, which express LGI1 endogenously at low levels, show so significant reduction in cell growth rate following transfection of the LGI1 gene. The proliferation potential was assessed using the SRB colorimetric assay by comparing the growth of each of the six individual clones with the parental and empty vector-transfected cells
LGI1 suppresses malignancy in glioma cells P Kunapuli et al there is a clear reduction in cell proliferation in all of the T98G and A172 clones carrying the LGI1 gene. In T98G, the growth rate of most clones was reduced to 10-30% (Po0.005) of that seen in cells transfected with the empty vector alone or the parental cells. The T98G FLAG6 clone showed reduced levels of expression and also demonstrated a milder suppression on cell growth potential, although still only 60% of that seen in the control cells. A minimal effect on cell proliferation was seen in the U87 cells that carry the exogenous LGI1 gene (Figure 4) , compared with cells from this line transfected with the empty vector or the parental cell line. Thus, the LGI1 gene clearly has the ability to suppress cell proliferation potential in glioma cell lines which do not express it endogeneously.
Cell migration assays
One of the hallmarks of GBM cells is that they begin to infiltrate surrounding normal brain tissue and so lose the constraints on cell migration. To test whether cell migration and infiltration capacity of glioma cells was affected by the reconstitution with LGI1, we performed BD matrigel matrix chamber assays, in triplicate, for each of the six clones from the three cell lines. The results shown in Figure 5 clearly demonstrate that all of the clones from the T98G and A172 glioma cells carrying LGI1FLAG almost completely lose their ability to invade and migrate through a matrigel matrix, compared to either the parental cells or the cells transfected with the empty vector. These assays clearly demonstrate that LGI1 can affect the invasive properties of glioma cells which have inactivated LGI1 during gliomagenesis, whereas LGI1 did not show any effect on the migration of U87 cells through the matrix.
Soft agar assays
Another feature of malignant cells is that they can grow under anchorage-independent conditions, the most common assay for this being the ability to grow and form colonies in soft agar. Glioma cells do not usually grow subcutaneously in immunecompromised mice (see Discussion) and so cannot be assayed for their malignant potential in vivo using this procedure. From the results shown in Figure 6 , it can be clearly seen that the parental cells and all of the clones from the T98G, A172 and U87 cell lines carrying the empty vector readily form colonies in soft agar. T98G and A172 cells carrying the LGI1-FLAG construct, however, have a greatly reduced capacity to form colonies. Thus, after 10 days, cells not expressing LGI1 formed numerous colonies compared to LGI1-expressing cells from T98G and A172 which, even after 20 days, only show restricted growth which did not progress. In contrast, U87 cells carrying the transfected LGI1 gene did not show any inhibition in the anchorage-independent growth potential. Taken together, these assays clearly demonstrate the ability of the LGI1 gene to suppress phenotypes related to the malignant potential.
Discussion
Multiple genetic alterations, including the loss of chromosome 10, are involved in the development of brain tumors. In this report, we clearly demonstrate, for the first time, that some of the important properties of glioma cells, which allow them to invade and metastasize, are significantly affected by the introduction of LGI1. The in vitro passage through the cell cycle, Figure 6 Soft agar assays for cells stably expressing the LGI1 gene, compared with glioma parental cell lines (P) and those transfected with the empty vector. Thus, T98G and A172 clones stably expressing LGI1 form significantly fewer colonies compared with the parental and vector-transfected cells. In contrast, introduction of LGI1 in to U87 (right) has no effect on the anchorge-independent growth of these cells, which shows no inhibition of colony-forming ability of these cells on the soft agar
LGI1 suppresses malignancy in glioma cells P Kunapuli et al however, was not completely suppressed by LGI1 in some cells, which might not have been expected since the loss of chromosome 10 material accompanies the acquisition of invasive potential in cells that have already overcome growth constraints by other mechanisms. Thus, although growth potential is suppressed by approximately X40% in cells null for LGI1 expression, their ability to migrate and invade a semisolid matrix is virtually abolished. This loss of the more aggressive phenotype is consistent with the observation that loss of chromosome 10 apparently accompanied the transition from low-to high-grade tumors.
Although it is assumed that loss of chromosome 10 represents the first hit in the heterozygous inactivation of a tumor suppressor gene, and that the remaining allele is inactivated by mutation, we were unable to demonstrate intragenic mutations in LGI1 in brain tumors (Somerville et al., 2000) , although structural rearrangements of LGI1 were detected at relatively high levels (Chernova et al., 1998) . Clearly, from our expression studies using RT-PCR (Chernova et al., 1998) and now Western blotting, loss of LGI1 expression occurs in a proportion of brain tumors and cell lines and probably occurs through methylation of critical control elements in the region 5 0 to the coding region (Somerville et al., 2000) . In cell lines that express LGI1, there is clearly some differential downregulation since expression levels are lower in these tumors compared with normal brain tissue. We have also shown in the T98GLGI1FLAG6 clone that the growth rate of cells depends on expression levels, which raises the possibility that, in some cells, inactivation of the remaining allele does not need to occur but rather that reduced levels of expression, as a result of haploinsufficiency for example, may be a factor that contributes to the progression of brain tumors. Some GBM tumors and cell lines express LGI1, demonstrating that there are other genetic routes to malignancy that do not depend on this gene. The fact that cells which normally express LGI1 are unaffected by the presence of another copy of the gene further supports the idea that inactivation of LGI1 is only one of the routes that glioma cells take to higher grade tumors. This observation provides the opportunity to compare gene expression profiles between cells that are responsive to suppression by LGI1 and those that are not.
The ultimate proof of loss of malignant potential is to use immune-compromised mice and demonstrate an inability to form tumors in vivo. Unfortunately, it has been consistently impossible to establish subcutaneous models for many glioma cell lines including T98G and A172, which means this assay was not available to us. It has been shown that some glioma cell lines will form tumors intracranially, although neither T98G nor A172 form tumors intracerebrally in the nude rat model (S Greenberg, personal communication) . Taken together, the in vitro assays described here have been used extensively in cancer research to analyse the malignant potential of cells, which clearly shows that LGI1 can suppress cell growth and invasion in glioma cells.
The LGI1 gene carries a number of specific motifs that give clues to its potential function. A signal peptide involving the first 35 amino acids and a putative transmembrane domain imply that this protein is transferred to the membrane and contains intracellular and extracellular components. In the extracellular domain, there is a leucine-rich repeat motif consisting of four repeat units flanked on either side by cystine-rich regions (Chernova et al., 1998) . This motif is typical of a family of genes that serves either as membrane receptors or that interact with the extracellular matrix (Buchanan and Gay, 1996) and serve to generate structural interactions as well as provide signaling clues to the cell relating to their position in the brain. The highest homology of LGI1 is with the Drosophila slit gene but only over the LRR region. In Drosophila, the slit is produced by the midline glial cells and is thought to be involved in axon guidance by regulating cell movement and processing of signaling clues from the matrix produced by the glial cells (Jacobs, 2000) . The slit contains EGF and Ig domains that provide clues to its signaling ability, but these domains are not present in LGI1, suggesting that, if it is capable of transducing extracellular signals through the intracellular domain, then this is through an as yet unknown mechanism. It is possible, however, that loss of function of LGI1 in some way allows tumors to escape from restraining interactions produced by the extracellular matrix in the brain and facilitates free movement.
A recent report by Krex et al. (2002) failed to demonstrate any suppression of the transition through the S phase in glioma cell lines following introduction of a retroviral construct incorporating LGI1 and EGFP. In these experiments, the transfection efficiency appeared to be very low and the cells analysed were selected only for the presence of green fluorescence. Unlike the experiments we have presented here, where we were able to demonstrate the presence of the protein product in transfected cells using Western blots, Krex et al. (2002) assumed that gene expression in the transfected cells was coincident with GFP. We have, however, frequently demonstrated that GFP constructs can dissociate and produce 'free' GFP in the cells. In the absence of any confirmation of the production of protein in their transfected cells, therefore, it cannot be definitively concluded that LGI1 protein is present. In addition, U87 cells were the only common cell line used between the two studies, which we clearly show is unaffected by expression of LGI1, presumably because of endogenous levels already present. The other cell lines used by Krex et al. (2002) , T1115, U373 and H4, were not included in our series but if they also express LGI1 it is unlikely that their malignant phenotype will be affected either. It is clear from the analysis of the FLAG6 clone from T98G that the levels of expression are important in response to the presence of LGI1 and so it is important to establish these levels before any comparison of data sets is possible.
